Satoshi Nori

Satoshi Nori

Auto-generated profile, based on publicly available information

Satoshi Nori

Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2021 in Regenerative Therapy
Verified
Journal Article
Open access
KSKeiko Sugai
Keiko Sugai
MSMiho Sumida
Miho Sumida
TSTomoko Shofuda
Tomoko Shofuda
RYRyo Yamaguchi
Ryo Yamaguchi
TTTakashi Tamura
Takashi Tamura
Hideyuki OkanoHideyuki Okano
Hideyuki Okano
Our group has conducted extensive basic and preclinical studies of the use of human induced pluripotent cell (iPSC)-derived neural stem/progenitor cell (hiPSC-NS/PC) grafts in models of spinal cord injury (SCI). Evidence from animal experiments suggests this approach is safe and effective. We are preparing to initiate a first-in-human clinical study of hiPSC-NS/PC transplantation in subacute SCI. NS/PCs were prepared at a Good Manufacturing Practice-grade cell processing facility at Osaka National Hospital using a clinical-grade integration-free hiPSC line established by the iPSC Stock Project organized by the Kyoto University Center for iPS Cell Research and Application. After performing all quality checks, the long-term safety and efficacy of cells were confirmed using immunodeficient mouse models. The forthcoming clinical study uses an open-label, single-arm design. The initial follow-up period is 1 year. The primary objective is to assess the safety of hiPSC-NS/PC transplantation in patients with subacute SCI. The secondary objective is to obtain preliminary evidence of its impact on neurological function and quality-of-life outcomes. Four patients with C3/4-Th10 level, complete subacute (within 24 days post-injury) SCI will be recruited. After obtaining consent, cryopreserved cells will be thawed and prepared following a multi-step process including treatment with a γ-secretase inhibitor to promote cell differentiation. A total of 2 × 106 cells will be transplanted into the injured spinal cord parenchyma 14–28 days post-injury. Patients will also receive transient immunosuppression. This study protocol has been reviewed and approved by the Certified Committee for Regenerative Medicine and the Japanese Ministry of Health, Labor and Welfare (University Hospital Medical Information Network Clinical Trials Registry [UMIN-CTR] number, UMIN000035074; Japan Registry of Clinical Trials [jRCT] number, jRCTa031190228). We plan to start recruiting a patient as soon as the COVID-19 epidemic subsides. The primary focus of this clinical study is safety, and the number of transplanted cells may be too low to confirm efficacy. After confirming safety, a dose-escalation study is planned.

24 June 2022 in The Spine Journal
Verified
Journal Article
Closed access
MYMitsuru Yagi
Mitsuru Yagi
TMTakehiro Michikawa
Takehiro Michikawa
TYTatsuya Yamamoto
Tatsuya Yamamoto
TITakahito Iga
Takahito Iga
YOYoji Ogura
Yoji Ogura
KWKota Watanabe
Kota Watanabe

26 July 2021 in Spinal Cord
Verified
Journal Article
Closed access
PDF file
NNNarihito Nagoshi
Narihito Nagoshi
OTOsahiko Tsuji
Osahiko Tsuji
SSSatoshi Suzuki
Satoshi Suzuki
SNSatoshi Nori
Satoshi Nori
MYMitsuru Yagi
Mitsuru Yagi
KWKota Watanabe
Kota Watanabe

23 April 2018 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
SNSatoshi Nori
Satoshi Nori
TSTateru Shiraishi
Tateru Shiraishi
RARyoma Aoyama
Ryoma Aoyama
KNKen Ninomiya
Ken Ninomiya
JYJunichi Yamane
Junichi Yamane
SUSeiji Ueda
Seiji Ueda

1 September 2020 in Journal of Orthopaedic Science
Verified
Journal Article
Closed access
SNSatoshi Nori
Satoshi Nori
RARyoma Aoyama
Ryoma Aoyama
KNKen Ninomiya
Ken Ninomiya
SSSatoshi Suzuki
Satoshi Suzuki
UAUkei Anazawa
Ukei Anazawa
TSTateru Shiraishi
Tateru Shiraishi

1 March 2020 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
SNSatoshi Nori
Satoshi Nori
TSTateru Shiraishi
Tateru Shiraishi
RARyoma Aoyama
Ryoma Aoyama
Comparison between muscle-preserving selective laminectomy and laminoplasty for multilevel cervical spondylotic myelopathy